www.prnewswire.com ·
investor alert pomerantz law firm reminds investors with losses on their investment in immunitybio inc of class action lawsuit and upcoming deadlines ibrx 302773059
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedThe lawsuit and FDA warning create legal and regulatory risk for ImmunityBio, potentially affecting its revenue from Anktiva and increasing compliance costs. The stock price decline reflects investor concern over sales and margin impact. No direct commodity or supply chain effects; impact is company-specific.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Class action lawsuit filed against ImmunityBio (IBRX) for securities fraud.
- FDA warning on March 13, 2026 regarding misleading promotions of bladder-cancer drug Anktiva.
- Stock price dropped $1.99 (21.12%) to $7.41 on March 24, 2026.
- Lead Plaintiff deadline: May 26, 2026.
Over the next 2-4 weeks, ImmunityBio may face margin compression and potential revenue decline from Anktiva due to compliance costs and prescriber delays.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- PHARMA_BIOTECHmid
- PHARMA_BIOTECHshort